Uterine leiomyosarcoma well-controlled with eribulin mesylate

Area of Science:

• Gynecologic Oncology
• Pharmacology
• Marine Natural Products

Background:

• Uterine leiomyosarcoma is a rare, aggressive gynecological cancer with limited treatment options and poor prognosis.
• Eribulin, a synthetic analogue of halichondrin B from a marine sponge, has shown promise in treating certain advanced solid tumors.

Observation:

• A 57-year-old woman with advanced uterine leiomyosarcoma (Stage IIB) underwent surgery and multiple lines of chemotherapy, including gemcitabine and docetaxel, with disease progression.
• Eribulin was administered as a fourth-line treatment, resulting in a 32% tumor mass reduction after four cycles.
• While eribulin demonstrated efficacy, tumor growth eventually resumed after eight cycles. The primary adverse event was mild neutropenia.

Findings:

• Eribulin demonstrated a partial response in a patient with recurrent, treatment-resistant uterine leiomyosarcoma.
• The drug was well-tolerated, with minimal adverse events and a good quality of life for the patient.
• This case highlights eribulin's potential as a salvage therapy for advanced gynecological sarcomas.

Implications:

• Eribulin may offer a viable treatment option for patients with advanced or recurrent uterine leiomyosarcoma, particularly when other therapies have failed.
• The favorable safety profile and ease of administration of eribulin support its consideration in treatment-naive and refractory settings.
• Further research is warranted to establish optimal dosing, treatment duration, and combination strategies for eribulin in gynecological sarcoma management.